That research led to the FDA granting compassionate use of the doxecitine and doxribtimine treatment in Arturito Estopinan, ...

The ESSENCE trial was intended to prove the efficacy of Vyondys 53 (golodirsen) and Amondys 45 (casimersen), which received ...

Shares in Metsera shot up nearly 20% to more than $72 after news of the renewed bidding war emerged, raising its market ...

The new $3 billion manufacturing facility will be sited at the Leiden Bio Science Park in Katwijk, and will be Lilly's first ...

Amid historic advances in cell-based therapies and precision medicine, biotech’s biggest challenge isn’t scientific, it’s ...

Today, POA Pharma is headquartered in Copenhagen, with additional facilities located across the Nordics and Germany. Galen ...

Roche and partner Klinrisk have picked up a CE-mark in the EU for an AI-based tool that can be used to predict renal function decline in patients with chronic kidney disease (CKD). The algorithm will ...

After filing one lawsuit to try to block Novo Nordisk's $9 billion effort to trump the takeover, Pfizer has returned to the ...

Tidmarsh, who was named as director of the Center for Drug Evaluation and Research (CDER) in July, told ABC in an interview ...

The results of the ALLEGORY trial of Gazyva (obinutuzumab) suggest that the anti-CD20 antibody could have broad utility in ...

As drug development becomes more complex, so do the demands for accurate, reproducible bioanalytical data to prove their ...

Neuropsychiatric disorder specialist MapLight Therapeutics has made its debut on the Nasdaq, raising $251 million and ...